Navigation Links
Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
Date:7/29/2010

EMERYVILLE, Calif., July 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba.

"We are pleased with the outcome of our Scientific Advice meetings with the European Medicines Agency. We are eager to put this guidance to use and to start our late stage pivotal studies for Menerba," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer.

"There are 37 million menopausal women in Europe and, with a European marketing authorization, we expect the European market demand to be strong for a safe and efficacious alternative to hormone therapy for the treatment of hot flashes," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer.

The Company has also had a meeting with the U.S. Food and Drug Administration (FDA) on the development of Menerba in the U.S., and looks forward to providing more details when the minutes of the meeting are released.

About Menerba

Menerba is an oral, botanically-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-beta) selective drug, developed as a safer alternative to the products currently
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
2. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
3. Bionovo Announces 2009 Highlights and Year-End Financial Results
4. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
5. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
6. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
7. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
8. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
9. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
10. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
11. Bionovo Announces First Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  BioPontis Alliance for Rare ... philanthropies, announced today the creation of a joint ... of the rare disease known as Charcot- Marie-Tooth ... alliance model earlier this month. Today,s partnership announcement ... collaborative model where researchers and all CMT dedicated ...
(Date:10/18/2014)... WASHINGTON , Oct. 18, 2014  In ... Human Rights Campaign (HRC), the nation,s largest lesbian, ... explicitly endorsed the use of Truvada for Pre-Exposure ... health tool used to prevent the spread of ... is the only brand name anti-HIV drug combination ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... of Up to Four Years of Treatment Presented ... Schering-Plough,Corporation (NYSE: SGP ) today reported ... receptor antagonist, demonstrated,sustained viral suppression and increased CD4 ... four years of therapy in treatment-experienced,HIV-infected patients. Vicriviroc ...
... 26 Paratek Pharmaceuticals, Inc. today,announced positive Phase ... a first-in-class aminomethylcycline (AMC). The Phase 2 study ... forms of PTK 0796 to,Zyvox(R) in the treatment ... (cSSSIs). Paratek,s trial met its primary safety and,tolerability ...
Cached Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that ... announced its latest designs of 2014 mother of ... elegant outfits are offered with big discounts, up to ... October 30 can enjoy this special offer. , ... it has become one of the leading brands in ...
(Date:10/19/2014)... 2014 Stephen T. Greenberg, M.D., with offices ... the 10th consecutive year as one of Long Island’s best ... also been nominated as the best provider for Botox injections. ... best Day Spa and best Laser Treatment center on Long ... readers can vote for the contest once per day, per ...
Breaking Medicine News(10 mins):Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... Nov. 12 Healthcare is an industry faced with ... how to overcome the noise and clearly communicate relevant ... marketing innovation company Griffin York & Krause (GY&K) reaffirmed ... it has been honored with six national CardioVascular Advertising ...
... Nov. 12 First Citizens Bank, a premier full-service ... into an agreement to provide a patient payment system ... , mPay Gateway,s software solution enables health care providers ... service and obtain payment authorization before a patient leaves ...
... so did incidence of abnormal cells in milk ducts, study ... of hormone replacement therapy may be driving down rates of ... for breast cancer, new research suggests. , This is the ... hyperplasia -- abnormal cells in the breast,s milk ducts -- ...
... more Canadians are diagnosed with H1N1 influenza infection, some will ... treated in the intensive care unit (ICU) and placed on ... from the infection. While mechanical ventilation clearly saves the ... cases, this supportive measure has been known to damage the ...
... Trinity ... and Milton Cato Memorial Hospital, announces the appointment of Dr. Ty-Asha Plummer to the ... to the Clinical Faculty of Trinity School of Medicine. , ... (PRWEB) November 12, 2009 -- Trinity ...
... ... with vital health information and free merchandise , ... Chicago, IL (PRWEB) November 12, 2009--The International Diabetes Foundation estimates 344 ... to the population of the United States, if you count California twice. 285 million ...
Cached Medicine News:Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 3Health News:First Citizens Bank to Offer mPay Gateway's Point-of-Care Patient Payment System to Its Health Care Customers 2Health News:Less HRT, Fewer Cases of Possible Breast Cancer Precursor 2Health News:Less HRT, Fewer Cases of Possible Breast Cancer Precursor 3Health News:Mechanical ventilation for patients with lung damage don't always work as planned 2Health News:Mechanical ventilation for patients with lung damage don't always work as planned 3Health News:Trinity School of Medicine Announces the Appointment of Ty-Asha Plummer, M.D. to the Clinical Faculty 2Health News:Trinity School of Medicine Announces the Appointment of Ty-Asha Plummer, M.D. to the Clinical Faculty 3Health News:In Time for World Diabetes Day, November 14, 2009 - New Website Empowers Diabetes Patients to Learn and Earn 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: